Vancouver, British Columbia — December 13, 2025 — Leads & Copy —
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) plans to amend 5,075,000 common share purchase warrants issued in a 2022 private placement. The amendment would change the exercise price of the warrants from US$1.75 to the Canadian equivalent of C$2.44.
The change is to align with NervGen’s functional currency and simplify accounting. All other terms of the 2022 warrants remain unchanged. The amended warrant terms are subject to TSX Venture Exchange acceptance.
NervGen has exclusive worldwide rights to NVG-291, a therapeutic peptide enabling nervous system repair. NVG-291 has received Fast Track designation from the FDA and Orphan Designation from the EMA for use in individuals with spinal cord injury. The company is evaluating NVG-291 in a Phase 1b/2a study for spinal cord injury.
Contacts:
Huitt Tracey, Investors
htracey@nervgen.com
604.537.2094
David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
Source: NervGen Pharma Corp.
